Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558
This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
This open-label, Phase I study will assess the safety and tolerability of surovatamig and characterise its PK and PD following subcutaneous administration to participants with RA or SLE.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- September 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Research Site · Fullerton, CA
Texas · 2
- Research Site · Allen, TX
- Research Site · Mesquite, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.